Advanced search
Publication Cover
Modern Rheumatology Case Reports Volume 4, 2020 - Issue 1
Journal homepage
91
Views
1
CrossRef citations to date
0
Altmetric
Case Reports

Vasculitis in a patient with mixed cryoglobulinemia treated with rituximab biosimilar CT-P10: a case report

Caterina VacchiRheumatology Unit, Azienda Policlinico di Modena, University of Modena and Reggio Emilia, Modena, Italy; Correspondence[email protected]
,
Andreina ManfrediRheumatology Unit, Azienda Policlinico di Modena, University of Modena and Reggio Emilia, Modena, Italy;
,
Carlo SalvaraniRheumatology Unit, Azienda Policlinico di Modena, University of Modena and Reggio Emilia, Modena, Italy; ;S.C. Reumatologia, Azienda USL-IRCCS Reggio Emilia, Reggio Emilia, Italy
&
Marco SebastianiRheumatology Unit, Azienda Policlinico di Modena, University of Modena and Reggio Emilia, Modena, Italy;
Pages 102-105 | Received 20 May 2019, Accepted 30 Oct 2019, Published online: 14 Nov 2019

References

  • Ferri C, Mascia MT. Cryoglobulinemic vasculitis. Curr Opin Rheumatol. 2006;18(1):54–63.
  • Roccatello D, Saadoun D, Ramos-Casals M, et al. Cryoglobulinaemia. Nat Rev Dis Primers. 2018;4(1):11.
  • Cacoub P, Comarmond C, Domont F, et al. Cryoglobulinemia vasculitis. Am J Med. 2015;128(9):950–955.
  • Ferri C, Sebastiani M, Giuggioli D, et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum. 2004;33(6):355–374.
  • Montero N, Favà A, Rodriguez E, et al. Treatment for hepatitis C virus-associated mixed cryoglobulinaemia. Cochrane Database Syst Rev. 2018;5:CD011403.
  • Zaja F, De Vita S, Mazzaro C, et al. Efficacy and safety of Rituximab in type II mixed delayed-type hypersensitivity reaction or serum sickness after Rituximab treatment cryoglobulinemia. Blood. 2003;101(10):3827–3834.
  • Dereure O, Navarro R, Rossi JF, et al. Rituximab-induced vasculitis. Dermatology. 2001;203(1):83–84.
  • Sène D, Ghillani-Dalbin P, Amoura Z, et al. Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. Arthritis Rheum. 2009;60(12):3848–3855.
  • Patel SV, Khan DA. Adverse reactions to biologic therapy. Immunol Allergy Clin North Am. 2017;37(2):397–412.
  • Greenwald M, Tesser J, Sewell KL. Biosimilars have arrived: Rituximab. Arthritis. 2018;2018:1–6.
  • Smitienko I, Novikov P, Moiseev S, et al. SAT0529 Short-term efficacy and safety of biosimilar Rituximab in patients with systemic vasculitides. Ann Rheum Dis. 2018;77:1120.
  • Kersh AE, Feldman RJ. Autoimmune sequelae following Rituximab therapy: a review of the literature and potential immunologic mechanisms. J Clin Rheumatol. 2018;24(8):427–435.
  • Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54(9):2793–2806.
  • Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of Rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006;54(5):1390–1400.
  • van Vollenjoven RF, Emery P, Bingham CO 3rd, et al. Extended report: long-term safety of Rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013;72:1496–1502.
  • D'Arena G, Simeon V, Laurenti L, et al. Adverse drug reactions after intravenous Rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients. Leuk Lymphoma. 2017;58(11):2633–2641.
  • Ramos-Casals M, Diaz-Lagares C, Cuadrado MJ, et al. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev. 2010;9(3):188–193.
  • Kandula P, Kouides PA. Rituximab-induced leukocytoclastic vasculitis: a case report. Arch Dermatol. 2006;142(2):246–247.
  • Kim MJ, Kim HO, Kim HY, et al. Rituximab-induced vasculitis: a case report and review of the medical published work. J Dermatol. 2009;36(5):284–287.
  • Desbois AC, Biard L, Sene D, et al. Rituximab associated vasculitis flare: incidence, predictors and outcome. J Rheumatol. 2019. doi:10.3899/jrheum.190076
  • Park W, Suh CH, Shim SC, et al. Efficacy and safety of switching from innovator Rituximab to biosimilar CT-P10 compared with continued treatment with CT-P10: results of a 56-week open-label study in patients with rheumatoid arthritis. BioDrugs. 2017;31(4):369–377.
  • Roy PS, John S, Karankal S, et al. Comparison of the efficacy and safety of Rituximab (Mabthera™) and its biosimilar (Reditux™) in diffuse large B-cell lymphoma patients treated with chemo-immunotherapy: a retrospective analysis. Indian J Med Paediatr Oncol. 2013;34(4):292–298.
  • Toogeh G, Faranoush M, Razavi SM, et al. A double-blind, randomized comparison study between Zytux™ vs MabThera® in treatment of CLL with FCR regimen: non-inferiority clinical trial. Int J Hematol Oncol Stem Cell Res. 2018;12(2):84–91.
  • Kim WS, Buske C, Ogura M, et al. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with Rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial. Lancet Haematol. 2017;4(8):e362–e373.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.